non fda approved glp 1 approves Lilly's Foundayo (orforglipron) GLP-1 pill for weight loss Ozempic® & Wegovy® (Semaglutide) Weight-Loss

To qualify, you must be 18, have Medicare Part D (prescription drug coverage) and meet the programs clinical criteria: A BMI of 35 or higher A BMI of 30 or higher and one or more of the following conditions: a diagnosis of heart failure with preserved ejection fraction, uncontrolled hypertension while on at least two blood pressure medications, or chronic kidney disease stage 3a or above A BMI of 27 or higher and one or more of the following conditions a diagnosis of pre-diabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease Those with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH (fatty liver disease) are ineligible for the Medicare GLP-1 Bridge program

Key players driving the GLP-1 market include Novo Nordisk, Eli Lilly, Pfizer, AstraZeneca, Roche, Sanofi, Boehringer Ingelheim, and Tonghua Dongbao Pharmaceutical

The raw numbers favor retatrutide

Of note, the Index of Relative Socioeconomic Disadvantage ranks areas in Australia based on information about income, education, employment, occupation, housing and other indicators [18]